Merck 4-week hep C regimen with Gilead's Sovaldi comes up short

November 10, 2014 12:05 AM

7 0

Nov 9 (Reuters) - An attempt by Merck & Co to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences Inc's huge selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study.

Several companies have been working to find ways to further reduce the number of weeks of treatment needed, while keeping cure rates above 90 percent.

Also read: European migration crisis gets super-power treatment in Cannes

Read more

To category page